Head and neck cancer patient-derived xenograft models

Head and neck cancer patient-derived xenograft models - A systematic review.:

Head and neck cancer patient-derived xenograft models - A systematic review.

Crit Rev Oncol Hematol. 2020 Sep 01;155:103087

Authors: Schuch LF, Silveira FM, Wagner VP, Borgato GB, Rocha GZ, Castilho RM, Vargas PA, Martins MD

Abstract

BACKGROUND: Patient-derived xenograft (PDX) involve the direct surgical transfer of fresh human tumor samples to immunodeficient mice. This systematic review aimed to identify publications of head and neck cancer PDX (HNC-PDX) models, describing the main methodological characteristics and outcomes.

METHODS: An electronic search was undertaken in four databases, including publications having used HNC-PDX. Data were analyzed descriptively.

RESULTS: 63 articles were yielded. The nude mouse was one most commonly animal model used (38.8 %), and squamous cell carcinoma accounted for the majority of HNC-PDX (80.6 %). Tumors were mostly implanted in the flank (86.3 %), and the latency period ranged from 30 to 401 days. The successful rate ranged from 17 % to 100 %. Different drugs and pathways were identified.

CONCLUSION: HNC-PDX appears to significantly recapitulate the morphology of the original HNC and represents a valuable method in translational research for the assessment of the in vivo effect of novel therapies for HNC.



PMID: 32992152 [PubMed - as supplied by publisher]